Bank stocks got a boost in the first week of October as upbeat economic data resulted in a widening ...
Upside's Best Buys in Clinical Research
05/21/2015 8:00 am EST
Medical advances and an aging population suggest health-related spending will remain on an uptrend, observes Richard Moroney, editor of Upside.
However, given their strong performance, now seems an especially bad time to chase second-tier health stocks. Today’s environment calls for selectivity. Two of our Best Buys are both involved in clinical research services.
ICON (ICLR) is our favorite healthcare pick. As a leading contract research organization (CRO), it performs clinical trials for healthcare companies.
The stock earns a 95 for Overall, second-highest among the 37 stocks in the life-sciences industry. Five of six Quadrix category scores exceed 80.
Analyst estimates have risen in sympathy with management’s bullish 2015 outlook, calling for per-share profits to jump 20% to 25% on sales growth of 7% to 9%.
ICON has reeled off 12 straight quarters of double-digit revenue growth, while operating profit margins have expanded in each of the past ten quarters. Pfizer accounted for 31% of ICON’s revenue last year.
ICON shares have soared 38% in 2015. That rally has pushed the trailing P/E ratio to a lofty 25, though it still offers a 4% discount to its five-year average and a 9% discount to its sector median. ICON is a Best Buy.
Parexel (PRXL) is another provider of clinical research services. Over the long-term, the company posts consistent growth in earnings and cash flow and enjoys a large backlog, as drug and biotech firm look to outsource research.
The stock slumped after reporting mixed results for its March quarter. Per-share earnings increased 18% to $0.66, matching the consensus.
Revenue rose only 2% and was below expectations but climbed 5% excluding unfavorable foreign currency movements. On March 31, the order backlog was $5.19 billion, up 5%.
For fiscal 2015 ending June, management trimmed its sales outlook but maintained earnings guidance, saying per-share profits should range from $2.65 to $2.83, implying at least 22% growth.
We also note that one of our favorite screens looks for short squeeze candidates. Paraxel has a short ratio above 10, which approximates the number of days needed to purchase all shorted shares based on average trading volume. Despite the mixed guidance, Parexel remains a Best Buy.
More from MoneyShow.com:
Related Articles on STOCKS
Insiders are starting to go radio silent in advance of the release of third-quarter operating result...
If tech has you down, consider the strong defense Big Pharma has been playing lately. The sector has...
Shares of industrial conglomerate General Electric (GE) jumped on the announcement that previous Cha...